ロード中...
Ribociclib-Induced Erythema Dyschromicum Perstans (Ashy Dermatosis)–Like Pigmentation in a Metastatic Breast Cancer Patient
Ribociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor that has been approved in combination with endocrine therapy for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative advanced or metastatic breast cancer. The main dermatological adverse events asso...
保存先:
| 出版年: | J Breast Cancer |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Korean Breast Cancer Society
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7920864/ https://ncbi.nlm.nih.gov/pubmed/33634626 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4048/jbc.2021.24.e1 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|